胎儿室上性心动过速的产前治疗:多中心试验
本研究为日本多中心单臂试验,纳入50例孕22至<37周、胎儿持续室上性心动过速或心房扑动≥180次/分的单胎妊娠,采用地高辛、索他洛尔和氟卡尼的协议定义经胎盘治疗。结果显示89.8%(44/49)胎儿心动过速缓解,但母体不良事件达78.0%,新生儿出生后2周内快速性心律失常发生率为31.9%。
要点
- 协议经胎盘治疗可使约90%胎儿室上性心动过速或心房扑动缓解。
- 母体不良事件常见(78.0%),严重不良事件可发生于胎儿并导致停药。
- 新生儿出生后2周内需警惕快速性心律失常复发(31.9%)。
核心结论
- 协议定义的经胎盘治疗对胎儿室上性心动过速和心房扑动在90%患者中有效且可耐受。
- 但需注意胎儿可能发生严重不良事件,且出生后2周内快速性心律失常可能复发。
研究设计与样本
- 多中心、单臂试验,2010至2017年日本15家机构纳入50例单胎妊娠,孕22至<37周,胎儿持续室上性心动过速或心房扑动≥180次/分。
- 协议治疗使用地高辛、索他洛尔和氟卡尼经胎盘给药。
- 主要终点为胎儿快速性心律失常缓解;次要终点包括胎儿死亡、早产和新生儿心律失常;同时评估不良事件。
主要发现
- 总体胎儿快速性心律失常缓解率为89.8%(44/49),胎儿水肿病例中缓解率为75.0%(3/4)。
- 早产发生率为20.4%(10/49)。
- 母体不良事件发生率为78.0%(39/50),严重不良事件发生于1名母亲和4名胎儿,导致4例患者停止协议治疗。
- 发生2例胎儿死亡,主要原因为心力衰竭。
- 新生儿出生后2周内快速性心律失常发生率为31.9%(15/47)。
临床怎么用
- 对于孕22至<37周、胎儿持续室上性心动过速或心房扑动≥180次/分的单胎妊娠,可考虑协议定义的经胎盘治疗。
- 治疗期间需监测母体不良事件,并警惕胎儿严重不良事件及停药可能。
- 新生儿出生后2周内应监测快速性心律失常复发。
局限性
- 单臂设计,无对照组。
- 样本量较小(50例),部分亚组例数少(如长VA室上性心动过速4例)。
- 研究仅在日本进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standardized treatment of fetal tachyarrhythmia has not been established. OBJECTIVES: This study sought to evaluate the safety and efficacy of protocol-defined transplacental treatment for fetal supraventricular tachycardia (SVT) and atrial flutter (AFL). METHODS: In this multicenter, single-arm trial, protocol-defined transplacental treatment using digoxin, sotalol, and flecainide was performed for singleton pregnancies from 22 to <37 weeks of gestation with sustained fetal SVT or AFL ≥180 beats/min. The primary endpoint was resolution of fetal tachyarrhythmia. Secondary endpoints were fetal death, pre-term birth, and neonatal arrhythmia. Adverse events (AEs) were also assessed. RESULTS: A total of 50 patients were enrolled at 15 institutions in Japan from 2010 to 2017; short ventriculoatrial (VA) SVT (n = 17), long VA SVT (n = 4), and AFL (n = 29). One patient with AFL was excluded because of withdrawal of consent. Fetal tachyarrhythmia resolved in 89.8% (44 of 49) of cases overall and in 75.0% (3 of 4) of cases of fetal hydrops. Pre-term births occurred in 20.4% (10 of 49) of patients. Maternal AEs were observed in 78.0% (39 of 50) of patients. Serious AEs occurred in 1 mother and 4 fetuses, thus resulting in discontinuation of protocol treatment in 4 patients. Two fetal deaths occurred, mainly caused by heart failure. Neonatal tachyarrhythmia was observed in 31.9% (15 of 47) of neonates within 2 weeks after birth. CONCLUSIONS: Protocol-defined transplacental treatment for fetal SVT and AFL was effective and tolerable in 90% of patients. However, it should be kept in mind that serious AEs may take place in fetuses and that tachyarrhythmias may recur within the first 2 weeks after birth.
引用
- Miyoshi T, Maeno Y, Hamasaki T, et al. Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. J Am Coll Cardiol. 2019. PMID: 31416531. doi:10.1016/j.jacc.2019.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。